LumiraDx Investor Presentation Deck
1 TB Molecular Program Demonstrates Feasibility to
Develop Swab Based POC Test
Key Targets and Workflow
Tongue swab sample
Results in 20 minutes
Access to testing for HIV+ and Pediatric
Populations, currently underserved
Performance Feasibility
Copy
number
(cp/rxn)
11
5.6
1.3
0.6
lumiraDx™
No of
positives
8/8
8/8
33/38
3/8
% positivity
100
100
87
33
Value Proposition
POC TB test has opportunity to increase patients linked to care
Number of patients at each step of cascade
5,000,000
4,500,000
4,000,000
3,500,000
3,000,000
2,500,000
2,000,000
1,500,000
1,000,000
500,000
0
2,840,000
100%
Individuals with
incident TB
1,938,027
Copyright © 2020 Lumiax Ltd. All Rights Reserved, Worldwide
Accessed TB
1,629,906
57%
1,417.838
50%
1,221,764
Diagnosed with
TB
Registered in
treatment
TB Care Cascade in Indian Public Health System
43%
B
Treatment
success
1,049,237
37%
Recurrence-free
survivalView entire presentation